Cure­Vac touts old­er adult da­ta for GSK-part­nered Covid-19, flu can­di­dates

Ger­many’s Cure­Vac re­port­ed da­ta Mon­day on old­er pa­tients to beef up plans to ad­vance vac­cines for Covid-19 and sea­son­al flu.

In short, the Covid-19 da­ta re­veal the vac­cine can­di­date, known as CV0501 tar­get­ing Omi­cron’s BA.1 vari­ant, boost­ed titers of neu­tral­iz­ing an­ti­bod­ies by 13.3-fold af­ter four weeks at the low­est 12 µg dose lev­el. The da­ta in these co­horts are still small, with 10 pa­tients en­rolled per dose. Some pa­tients al­so re­ceived 25 and 50 µg dos­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER